Cargando…

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV

OBJECTIVE: The present study aims to investigate the correlation between the gene polymorphisms of the multidrug resistance protein 1 (ABCB1), the intron region of transcriptional factor (GTF2E1) and catechol-O-methyltransferase (COMT), dopamine receptor (DRD2), and the control of chemotherapy-induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Yilan, Jin, Gaowa, Zhao, Jun, Jiang, Caihong, Zhao, Lanzhen, Jiang, Ying, Chen, Feng, Li, Hui, Wang, Wenjuan, Wu, Yungaowa, Liu, Guang, Li, Xiaorong, Gu, Min, Li, Xiaomei, Li, Quanfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289460/ https://www.ncbi.nlm.nih.gov/pubmed/34290520 http://dx.doi.org/10.2147/PGPM.S317229

Ejemplares similares

A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting
por: Liu, Guang, et al.
Publicado: (2022)

Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study
por: Gao, Jiali, et al.
Publicado: (2022)

An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and Vomiting
por: Jin, Yilan, et al.
Publicado: (2021)

The emerging role of olanzapine in paediatric CINV control: A review
por: Barušić, Anabella Karla
Publicado: (2022)

Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting
por: Li, Quanfu, et al.
Publicado: (2018)

A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
por: Jin, Yilan, et al.
Publicado: (2023)

Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
por: Giagnuolo, Giovanna, et al.
Publicado: (2019)

Prophylactic administration of recombinant human thrombopoietin attenuates XELOX or SOX regimen-induced thrombocytopaenia
por: Li, Quanfu, et al.
Publicado: (2021)

The Clinical Observation of Acupuncture Combined With Antiemetic Drugs in the Prevention and Treatment of CINV in Breast Cancer Patients
por: Kong, Fanming, et al.
Publicado: (2022)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
por: Botteman, Marc, et al.
Publicado: (2019)

Guidelines versus individualized care for the management of CINV
por: Clemons, Mark
Publicado: (2018)

Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study
por: Kawazoe, Hitoshi, et al.
Publicado: (2018)

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India
por: Babu, Govind, et al.
Publicado: (2016)

Mitochondrial energy metabolism correlates with an immunosuppressive tumor microenvironment and poor prognosis in esophageal squamous cell carcinoma
por: Zhang, Zewei, et al.
Publicado: (2023)

CINV: still troubling patients after all these years
por: Aapro, Matti
Publicado: (2018)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
por: Chang, Jianhua, et al.
Publicado: (2020)

Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide
por: Suehiro, Marii, et al.
Publicado: (2021)

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
por: Yang, Meng-Jie, et al.
Publicado: (2020)

Erratum: The clinical observation of acupuncture combined with antiemetic drugs in the prevention and treatment of CINV in breast cancer patients
Publicado: (2022)

Preparation and Characterization of Aprepitant Solid Dispersion with HPMCAS-LF
por: Liu, Jinwen, et al.
Publicado: (2022)

Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
por: D’Souza, Anita, et al.
Publicado: (2020)

Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
por: Yeo, Winnie, et al.
Publicado: (2020)

Helping patients discuss CINV management: development of a Patient Charter
por: Young, Annie, et al.
Publicado: (2013)

Preparation and in vivo evaluation of an intravenous emulsion loaded with an aprepitant-phospholipid complex
por: Li, Yan, et al.
Publicado: (2023)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
por: Zhang, L, et al.
Publicado: (2018)

The interaction of ifosfamide and aprepitant in gynecologic malignancies()
por: Shindorf, Mackenzie L., et al.
Publicado: (2013)

Aprepitant for the Treatment of Chronic Refractory Pruritus
por: He, Alice, et al.
Publicado: (2017)

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
por: Rashad, Noha, et al.
Publicado: (2017)

Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
por: Shivaprakash, G., et al.
Publicado: (2017)

Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor
por: Zheng, Yang, et al.
Publicado: (2023)

Pulmonary Thromboembolism Associated with Olanzapine Treatment
por: Wang, Qian, et al.
Publicado: (2015)

Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice
por: Warr, David
Publicado: (2018)

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study
por: Zhao, Lei, et al.
Publicado: (2023)

Dynamic changes in the body composition during chemotherapy for gastrointestinal tumors in the context of active nutrition intervention
por: Xu, Ting, et al.
Publicado: (2022)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome
por: Parvataneni, Swetha, et al.
Publicado: (2019)

The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone
por: Lee, Se-Jin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j6a23hdd09tlofhn3h18nulle4